VTX-801 is an AAV-based gene therapy for Wilson’s disease. VTX-801 contains a corrective version of the ATP7B gene, which is malfunctioning in patients affected with Wilson’s disease, and is currently under clinical evaluation in a Phase 1/2 clinical safety and efficacy study (GATEWAY) with a 12-week readout. VTX-801 received US and EU Orphan Drug Designation (ODD), and fast track designation by FDA.
VTX-PID is a technology aimed to deplete Neutralizing Antibodies (NAbs) levels for a given AAV serotype, to a level allowing proper AAV transduction and therefore desired efficacy. VTX-PID is developed both for patients presenting NAbs because of a previous infection and therefore non eligible for gene therapy; and for patients in need of gene therapy re-administration in case of loss of efficacy.
Vivet Therapeutics has investors from both sides of the ocean, bringing strong support, network and long-term commitment.
Vivet is a strong team of experienced scientists and technical experts who are passionate about innovative science and dedicated to improving patients’ lives by curing genetic disorders. We have a unique pipeline of liver-directed AAV products, as well as solid technological platforms which allow us to unlock the full potential of gene therapy.
We are constantly looking for new ideas. Today, we live in an era of extraordinary progress and innovation where we can drive science to create extraordinary opportunities for patients and their families.
Through the unique design of the GATEWAY trial, we intent to demonstrate the effectiveness of our lead asset, VTX-801, to restore copper homeostasis in Wilson disease patients. The innovative use of a biomarker will allow for a quick readout of treatment response that will trigger standard of care treatment withdrawal.
Vivet is a strong team of experienced scientists and technical experts who are passionate about innovative science and dedicated to improving patients’ lives by curing genetic disorders. We have a unique pipeline of liver-directed AAV products, as well as solid technological platforms which allow us to unlock the full potential of gene therapy.
We are constantly looking for new ideas. Today, we live in an era of extraordinary progress and innovation where we can drive science to create extraordinary opportunities for patients and their families.
Through the unique design of the GATEWAY trial, we intent to demonstrate the effectiveness of our lead asset, VTX-801, to restore copper homeostasis in Wilson disease patients. The innovative use of a biomarker will allow for a quick readout of treatment response that will trigger standard of care treatment withdrawal.
gene therapy
Program
years of cumulated
Experience
Paris, France, July 16, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic
We are delighted to share our findings in a peer reviewed paper published in the World Journal of Hepatology, titled ‘Characteristics of patients with Wilson
Vivet Therapeutics Presents Interim Data from its Phase 1/2 GATEWAY Trial for the Treatment of Wilson Disease at EASL Congress 2024 VTX-801 increased ceruloplasmin ferroxidase
As Co-founder and Chief Scientific Officer of #VivetTherapeutics, Dr @Gloria Gonzalez-Aseguinolaza will be presenting 📢 at the upcoming #CTX Scientific & Family Meeting
🎓Are you attending the upcoming @EASL Congress 2024, the home of Hepatology, from 5-8 June in Milan, Italy! Don’t miss the opportunity to meet the
Join Sonia VALERO, Head of Clinical Operations and Patient Advocacy Representative at Vivet Therapeutics’ at the 4th Annual Gene Therapy Patient Engagement Summit in Boston,
